However, it is also involved in medicine commerce. Sun Piaoyang has witnessed his fortune rise by nearly 30% throughout the last year on business gains stemming from the company’s production of cancer-related drugs. After the first-half revenue went up 14% to $485 million, net profit subsequently rose 15% to $105 million.